

Re: Impactor hydrogel update

Frieman, Matthew <MFrieman@som.umd.edu>

Thu 7/23/2020 12:43 AM

To:Paul Jacob Bueno de Mesquita <jbueno@umd.edu>
Cc:dmilton@umd.edu <dmilton@umd.edu>

I really don't know what this layer should be. I would say as sterile as possible knowing that its going to be contaminated with fungi, bacteria etc in the air through the collector.

Matt

On Jul 22, 2020, at 1:16 PM, Paul Jacob Bueno de Mesquita <jbueno@umd.edu> wrote:

Hi Matt,

Don verified through a Slack message that what I've described is correct -- we are interested in this mucin layer to be used on our 5micron impactor plate to facilitate culture of SARS-CoV-2 in our current work as well as future work with flu and other respiratory pathogens.

We seek your advice regarding what might be helpful in terms of preserving virus for culture. For example, how sterile should the mucin be? Are there any components in the mucin layer that we should be considering in terms of downstream culture work? I'm being asked these questions by Katherine Joyner from Gregg Duncan's lab, who is actually generating the mucin.

Basically, we are going to be sending you the samples for culture and want to get your input on what might set you up for success in terms of the mucin matrix media on which the samples are collected.

Previously I don't think we have not been sending your 5micron impactor plate samples for culture because there is little chance of those producing culturable virus given the way they the particles are collected onto the teflon plate with high airflow for 30 minutes and then scrubbed off with a swab (per Michael Grantham's experience with flu).

Does this make sense?

Please let me know if I can try to clarify anything further.

We appreciate your help!

Jake

On Wed, Jul 22, 2020 at 11:17 AM Paul Jacob Bueno de Mesquita <jbueno@umd.edu> wrote:

Hi Matt,

Thanks for following up. We are working on adding a mucin layer to the 5μm teflon impactor plates that we use for collecting coarse aerosols in the G2. The goal is to be able to culture virus from these mucin impregnated plates. Previously we haven't been able to culture virus from plain teflon impactors.

I believe this work will support ongoing SARS-CoV-2 sample collection as well as collection of flu and other respiratory viruses later on.

Dr. Milton, please verify that I am describing this appropriately. I'm afraid I have not had available the information required to fully understand how this project fits within the context of broader grant projects/deliverables and this may help clarify things for Matt.

Thanks,

Jake

On Wed, Jul 22, 2020 at 10:19 AM P. Jacob Bueno de Mesquita <jakebuenodem@gmail.com> wrote:

----- Forwarded message -----

From: Frieman, Matthew <MFrieman@som.umd.edu>
Date: Wed, Jul 22, 2020 at 8:53 AM
Subject: Fwd: Impactor hydrogel update
To: Jacob de Mesquita <jakebuenodem@gmail.com>

Can you give me the brief rundown about what this is all about?

Matt

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St

Room 380
Baltimore, MD 21201

office: [410-706-2539](tel:410-706-2539)

Begin forwarded message:

From: Katherine Joyner <kajoyer@umd.edu>
Date: July 22, 2020 at 8:09:00 AM EDT
To: Paul Jacob Bueno de Mesquita <jbueno@umd.edu>
Cc: Kevin Aroom <karoom@umd.edu>, dmliton@umd.edu <dmliton@umd.edu>, "Frieman, Matthew" <MFrieman@som.umd.edu>, Gregg Duncan <gaduncan@umd.edu>, Jennifer Rebecca German <jgerman@umd.edu>, Sheldon Tai <sta1@umd.edu>
Subject: Re: Impactor hydrogel update

Hi Kevin,

The cartridges fit so well! I think 20 would be enough to test the gel formulations and downstream processing.

Thanks,
Katherine

On Tue, Jul 21, 2020 at 9:42 PM Paul Jacob Bueno de Mesquita <jbueno@umd.edu> wrote:
Hi Kevin,

Sounds like it could help to get some cartridges.

They would probably go to Kat for her to play around with the mucin matrix.

Kat, how many cartridges would you like?

Thanks,

Jake

On Tue, Jul 21, 2020 at 8:26 PM Kevin Aroom <karoom@umd.edu> wrote:
Should I print out a bunch more of the cartridges tomorrow? My availability will start to get more limited next week so I'd like to keep the momentum going.

On Mon, Jul 20, 2020 at 9:51 PM Paul Jacob Bueno de Mesquita <jbueno@umd.edu> wrote:
Hi Kevin and Kat,

Thank you very much for bringing over the mucin adapted impactor plate for the G-II.

We ran the G-II with a 5µm impactor plate containing a thin layer of mucin. It appeared unaltered after a 30-minute test.

We ran the G-II with a 5µm impactor plate containing a thicker layer of mucin. It also appeared unaltered after a 30-minute test.

Kat had some questions about the composition of the mucin with respect to downstream sample processing, qRT-PCR, and culture. Would it be most helpful for the mucin to be as sterile as possible? Kat can explain what this means with respect to her workflow.

We also talked about what might be involved in isolating the virus from the mucin -- likely some vortexing with PBS + BSA, but this is also something to explore and get a protocol worked out.

I'm adding virology experts Matt, Sheldon, and Jennifer, who may offer some advice regarding the composition and preparation of the mucin layer to optimize downstream culture and PCR steps.

Kat, I hope Matt, Sheldon, and/or Jennifer can help answer some of your questions and we can continue discussing through this thread? If a conference call would help, I can set it up.

Thanks,

Jake

On Mon, Jul 20, 2020 at 11:53 AM Paul Jacob Bueno de Mesquita <jbueno@umd.edu> wrote:
Hi Kevin,

As a first test, we would like to run the machine with the part assembled to test how well the mucin layer remains intact during exposure to the airflow from the machine.

Perhaps next we can try aerosolizing some flu virus and testing capture efficiency, etc.

Kevin, today, if you're available I could meet you at our lab around 4:30 or 5pm? Otherwise I could be available tomorrow.

Thanks,

Jake

On Mon, Jul 20, 2020 at 10:05 AM Gregg Duncan <gaduncan@umd.edu> wrote:
Very exciting, thanks all for putting this together!

Gregg Duncan, PhD
Assistant Professor
Fischell Department of Bioengineering
University of Maryland
301-405-7397
gaduncan@umd.edu
<http://duncan.umd.edu>

> On Jul 20, 2020, at 8:58 AM, Kevin Aroom <karoom@umd.edu> wrote:
>
> We have made several 3D printed 'cartridges' that contain the mucin hydrogel, which were loaded friday morning. Also milled out one of the PTFE impactors to allow the cartridges to fit.
>
> The first set of 3D printed parts may have been a little porous, so I think some of the gel leaked out.
>
> Another 3D printer that can make watertight parts was down earlier, but I fixed it yesterday and have printed some more cartridges.
>
> I suggest we bring over what we have made thus far to check for any issues prior to loading the newer cartridges. Jake what is your schedule today?
>
> --
> Kevin Aroom MS, PE
> University of Maryland
> Robert E. Fischell Institute for Biomedical Devices
>
>
> <IMG_4417.JPG><IMG_4454.JPG><IMG_4415.JPG>

--
P. Jacob Bueno de Mesquita, PhD
Postdoctoral Researcher
Maryland Institute for Applied Environmental Health
School of Public Health | University of Maryland, College Park
jbueno@umd.edu | 401.932.1950
<https://go.umd.edu/stopcovid>

--
P. Jacob Bueno de Mesquita, PhD
Postdoctoral Researcher
Maryland Institute for Applied Environmental Health
School of Public Health | University of Maryland, College Park
jbueno@umd.edu | 401.932.1950
<https://go.umd.edu/stopcovid>

--
Kevin Aroom MS, PE
University of Maryland
Robert E. Fischell Institute for Biomedical Devices

--
P. Jacob Bueno de Mesquita, PhD
Postdoctoral Researcher
Maryland Institute for Applied Environmental Health
School of Public Health | University of Maryland, College Park
jbueno@umd.edu | 401.932.1950
<https://go.umd.edu/stopcovid>

--
Katherine Joyner, PhD
Postdoctoral Associate
Fischell Department of Bioengineering
University of Maryland
kajoyner@umd.edu

--
P. Jacob Bueno de Mesquita
jakebuenodem@gmail.com

--
P. Jacob Bueno de Mesquita, PhD
Postdoctoral Researcher
Maryland Institute for Applied Environmental Health
School of Public Health | University of Maryland, College Park
jbueno@umd.edu | 401.932.1950
<https://go.umd.edu/stopcovid>

--
P. Jacob Bueno de Mesquita, PhD
Postdoctoral Researcher
Maryland Institute for Applied Environmental Health
School of Public Health | University of Maryland, College Park
jbueno@umd.edu | 401.932.1950
<https://go.umd.edu/stopcovid>

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

Lab meeting on Slack today

Frieman, Matthew <MFrieman@som.umaryland.edu>

Wed 11/11/2020 9:49 AM

To:Frieman Lab <FriemanLab@SOMUMaryland.onmicrosoft.com>

Hi all

First, today is Veterans Day. We all thank Rob for his service.

Second, since there is a big mouse harvest today, lets push lab meeting to Slack instead.

I have 2 things to discuss, will put them on Slack now.

Matt

Matthew Frieman

Department of Microbiology and Immunology

University of Maryland School of Medicine

685 West Baltimore St, Room 380

Baltimore, MD 21201

 Print  Close

grant tips

Frieman, Matthew <MFrieman@som.umaryland.edu>

Tue 2/4/2020 10:24 PM

To: Jill Fahrner <jfahrne1@jhmi.edu>

 1 attachments (7 MB)

faculty writing tutorial 2019-external.pptx;

Matthew Frieman, PhD
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539

[REDACTED]

grant tips

Frieman, Matthew <MFrieman@som.umaryland.edu>

Tue 2/4/2020 10:24 PM

To: Jill Fahrner <jfahrne1@jhmi.edu>

1 attachments (7 MB)

faculty writing tutorial 2019-external.pptx;

Matthew Frieman, PhD
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539

[REDACTED]

grant tips

Frieman, Matthew <MFrieman@som.umaryland.edu>

Tue 2/4/2020 10:24 PM

To: Jill Fahrner <jfahrne1@jhmi.edu>

1 attachments (7 MB)

faculty writing tutorial 2019-external.pptx;

Matthew Frieman, PhD
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539

[REDACTED]

grant tips

Frieman, Matthew <MFrieman@som.umaryland.edu>

Tue 2/4/2020 10:24 PM

To: Jill Fahrner <jfahrne1@jhmi.edu>

1 attachments (7 MB)

faculty writing tutorial 2019-external.pptx;

Matthew Frieman, PhD
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539

[REDACTED]

grant tips

Frieman, Matthew <MFrieman@som.umaryland.edu>

Tue 2/4/2020 10:24 PM

To: Jill Fahrner <jfahrne1@jhmi.edu>

1 attachments (7 MB)

faculty writing tutorial 2019-external.pptx;

Matthew Frieman, PhD
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539

[REDACTED]

grant tips

Frieman, Matthew <MFrieman@som.umaryland.edu>

Tue 2/4/2020 10:24 PM

To: Jill Fahrner <jfahrne1@jhmi.edu>

1 attachments (7 MB)

faculty writing tutorial 2019-external.pptx;

Matthew Frieman, PhD
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539

[REDACTED]

Re: Opinion | We Can Safely Restart the Economy in June. Here's How. - The New York Times

Frieman, Matthew <MFrieman@som.umaryland.edu>

Sun 3/29/2020 12:54 PM

To:John Chamberlin <jchamberlin@observatorygroup.com>

Thanks, and good luck!

On Mar 29, 2020, at 12:12 PM, John Chamberlin <jchamberlin@observatorygroup.com> wrote:

Good question. My Japanese partner thinks Japan has weathered the storm much better than the US or Europe. He thinks it has to do with Japanese hygiene, number of ICU beds, etc.. But cases are rising and the jury's still out. Also, Japan has been fighting deflation for decades. They already have huge debt/GDP (200% v. 100% US) and the central banks own large amount of the country's equities (the Fed has not crossed this line, does not own equities). Europe was already near recession due to other factors before this, so I wouldn't be optimistic on Europe. But Europe does have "automatic stabilizers", essentially very generous unemployment payments that kick in automatically when there are layoffs, so Europe will have less social unrest than the US. The flipside is that the US' "creative destruction", where you allow weak companies to fail, usually means the US bounces back faster and more powerfully than Europe.

From an investment perspective, I think certain companies and sectors will be big winners rather than countries. Anything that involves working from home should do well no matter how long this lasts, since some of the work from home practices will certainly survive the recovery. Amazon from what I hear is on fire, hiring 100K+, unable to fill demand globally. Companies like Zoom, Slack, Microsoft, Netflix, Apple, all should do incredibly well during and after this. I would be short commercial real estate. Even once this is over, many businesses will choose to operate remotely. Hope this helps. For what it's worth, I'm buying more Amazon and the Nasdaq QQQ.

From: "Frieman, Matthew" <MFrieman@som.umaryland.edu>

Date: Sunday, March 29, 2020 at 11:41 AM

To: John Chamberlin <jchamberlin@observatorygroup.com>

Subject: Re: Opinion | We Can Safely Restart the Economy in June. Here's How. - The New York Times

I didn't think of the idea that this is happening everywhere in the world so as debt rises everywhere the idea would be that the US would still be the best to stay afloat should anything happen. That actually makes me feel better about the economic outlook here than worse. So all economies are worse off but the trajectory back up is better for the US than most other places. And there are probably places that are going to weather this better than the US, but where are those and for investors how do they find those places?

You have a weird job!

On Mar 29, 2020, at 11:12 AM, John Chamberlin <jchamberlin@observatorygroup.com> wrote:

Good points. On your economic question, I haven't seen any modeling yet on how we look afterwards. It's so path dependent as you point out..do we stop at \$2T, or do we then go to \$10T, \$20T, and how do we get there? When does economic activity resume? Does it go from 30% activity up to 60 or 70%? Straight to 99%? 8 weeks away, or 18 months? All these will be important factors.

In the meantime, I assume we do even more massive fiscal spending. You've probably seen that there is already work in the legislature for the next package, even before the ink is dry on the \$2T.

All those millions of laid off people have to eat, pay for energy, rent, wifi, etc. \$1200 won't go far.

My guess is the \$1200 will have to be repeated and probably increased. State budgets are collapsing along with tax revenue, so the states will also need tremendous cash infusions just to tread water. Companies large and small won't be able or willing to survive just on cheap loans.

Imagine burning through all your cash and then deciding to take out a loan as demand evaporates.

That's not how businesses operate. Many owners will prefer to shut down completely, save whatever cash they have by issuing mass layoffs, and then re-starting when the coast is clear rather

than taking out huge loans with no visibility on when business will return. The Fed can make loans, but you need demand for those loans if they're to be effective. I think it will require outright grants of cash from the Treasury, like what Denmark is doing (govt. is providing 75% of payroll in grants in exchange for no layoffs).

The fear around deficits is that investors get worried about big debtors and charge them a higher risk premium to lend, i.e., higher interest rates. This should also mean that the dollar sells off as investors worry more about exploding US deficits. But this assumes there are other countries and currencies with less risky practices to pile into. Since the whole world is moving simultaneously to drastically increase deficits, there should be an equilibrium. In other words, I don't think the dollar is at risk of collapsing just because we spend another \$20T on cash infusions to the economy. The Fed is also there to buy unlimited amounts of debt, so the yields aren't at risk of spiking upward since the Fed can smash them.

Net net, I don't see any alternative to tremendous, unprecedented deficit spending. My suspicion is that the social safety net and healthcare system will be much closer to a European model by the end of this than what we started with.

From: "Frieman, Matthew" <MFrieman@som.umd.edu>

Date: Sunday, March 29, 2020 at 10:40 AM

To: John Chamberlin <jchamberlin@observatorygroup.com>

Subject: Re: Opinion | We Can Safely Restart the Economy in June. Here's How. - The New York Times

There is a strange calculus emerging. Do we sacrifice the elderly and adults to this virus, leading to a raise in the death rate and risk health care workers to this virus who have to deal with this influx of cases?

Or do we pretend that a short term release of people so they can buy things at stores is worth it for the economy.

Just because the virus isn't in DeMoine (or pick your mid western city) now, doesn't mean that it won't be in 2 weeks. Do you want to minimize the risk to humans here or have a bolus of cases all at one time. If we have a surge in every city, hospitals will be crushed. If you have a surge in a 1 hospital city, it's over for them.

There are no good solutions to this.

I am not an economist and I don't know what a \$10T stimulus now would do to this country 2 years from now. Any modeling on what that actually does to us here and our economic power in the world?

On Mar 29, 2020, at 10:33 AM, John Chamberlin <jchamberlin@observatorygroup.com> wrote:

Thanks Matt.

My takeaway is that he believes we are very late in responding, and that optimal health and economic policy now requires maximum suppression/national quarantine until at least June 1 (8-10 weeks). Given that Trump is in favor of opening 14 days from now, and is playing to his base which still believes this is just a liberal hoax, I see no

chance of Emmanuel's 8-10 week national quarantine taking place. Therefore, the successive waves seems to be the most likely outcome.

But let's see. As the deaths increase and the hot spots shift from New York to other cities that aren't in blue states, maybe Trump will have a change of heart? Hard to say how public opinion will shift.

Best, John

From: "Frieman, Matthew" <MFrieman@som.umaryland.edu>
Date: Sunday, March 29, 2020 at 7:17 AM
To: John Chamberlin <jchamberlin@observatorygroup.com>
Subject: Opinion | We Can Safely Restart the Economy in June. Here's How. - The New York Times

<https://www.nytimes.com/2020/03/28/opinion/coronavirus-economy.html>

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: [410-706-2539](tel:410-706-2539)
[REDACTED]

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

Matthew Frieman, PhD

Associate Professor

Department of Microbiology and Immunology

University of Maryland School of Medicine

685 West Baltimore St

Room 380

Baltimore, MD 21201

office: 410-706-2539

[REDACTED]

Re: Quick email Request from Agence France-Press//FW: AFP fact-checking journalist - masks

Frieman, Matthew <MFrieman@som.umd.edu>

Thu 4/30/2020 10:25 AM

To:Kotz, Deborah <DKotz@som.umd.edu>

I dont know the data behind those numbers so I cant respond.

Matt

On Apr 30, 2020, at 10:17 AM, Kotz, Deborah <DKotz@som.umd.edu> wrote:

Hi Matt,

Do you have a moment to look at these images circulating on twitter and write a few sentences on whether they are correct or not? They're both pretty much the same. They suggest that if a Covid19 carrier does not wear a mask the chance of infecting a person next to them is 70% vs. 5% infection risk if they wear a mask and a 1.5% infection risk if both are wearing masks.

We can send a response via email and she'll quote you. I think she finds these images to be dubious which is why she's writing a "fact checking" piece on them. She's on deadline for today.

If you don't have time to do this, let me know and I'll reach out to other folks. Thanks!

From: Claire SAVAGE <Claire.SAVAGE@afp.com>

Sent: Thursday, April 30, 2020 9:49 AM

To: Kotz, Deborah <DKotz@som.umd.edu>

Subject: AFP fact-checking journalist - masks

Hi Deborah,

Thank you so much for your help. As I mentioned, I'm a fact-checking journalist with Agence France-Presse in Washington, DC.

I'm evaluating the veracity of images circulating on social media (attached) claiming specific contagion risk percentages for COVID-19 carriers wearing masks vs. not wearing masks. Can you please connect me with an expert who can comment?

If you could answer at your earliest convenience, that would be great.

Thanks again very much for your help.

All the best,

Claire SAVAGE

Fact-Checking Reporter

AFP Fact Check

440.263.4126

claire.savage@afp.com

<masks fb.png><slack-imgs.jpg>

Matthew Frieman, PhD

Associate Professor

Department of Microbiology and Immunology


University of Maryland School of Medicine

685 West Baltimore St

Room 380

Baltimore, MD 21201

office: 410-706-2539



Re: coronavirus workshop

Frieman, Matthew <MFrieman@som.umaryland.edu>

Wed 6/10/2020 3:11 PM

To:Fehr, Anthony <arfehr@ku.edu>

Cc:Channappanavar, Rudragouda <rchanna1@uthsc.edu>

This isn't an ASV sponsored event? If that's the case, do we have to limit it to people that submitted abstracts to ASV? There are several Baric lab people who didn't submit abstracts but could give great talks and I am sure we could easily find people quickly if it wasn't limited to only abstracts.

This all seems to be pretty odd to me.

On Jun 10, 2020, at 3:08 PM, Fehr, Anthony <arfehr@ku.edu> wrote:

Matt,

My student has agreed to switch sessions to give us a female presenter. I will adjust the program accordingly. We reached out to Stephanie (see below) and she has agreed with our efforts and that this happened by chance. Based on her earliest responses it seems that our session is an outlier. Also, she mentioned on our slack conversation that this is not an ASV-sponsored event. She also mentioned that the abstracts are assigned to a workshop based on preference by the submitter, so ASV does not take into consideration male/female splits when assigning the workshops. This may be something to bring up with ASV officers if you think it needs to be changed.

Tony

From: "Karst,Stephanie" <skarst@ufl.edu>

Date: Wednesday, June 10, 2020 at 11:49 AM

To: "Fehr, Anthony" <arfehr@ku.edu>

Subject: Re: coronavirus workshop

Tony, I think switching your student would be fine if Emily is OK with. Alternatively, did you invite the coronavirus poster abstract presenters to give talks? There are 14 of those.

But honestly I don't think you should feel obligated to do anything. Considering that we assign abstracts to a given workshop based on the submitter's preference and you invited everyone to participate this was really just by chance. I've queried the other workshop hosts and have started to get some responses. So far there is one with 5F/4M with 1F/3M declining and another with 8F/4M speakers (not sure about declines) so coronas may indeed be an outlier.

Stephanie

From: Fehr, Anthony <arfehr@ku.edu>
Sent: Wednesday, June 10, 2020 12:29 PM
To: Karst,Stephanie
Subject: Re: coronavirus workshop

[External Email]

Stephanie,

Would it be possible to ask some other session, maybe innate immune sessions if they have any abstracts related to CoVs by female authors that were not chosen for a talk. My guess is not, as I think most of the groups offered all talks and posters the ability to speak in the virtual session.

As an alternative, I may propose to my female student who is schedule to speak in the Interference with Host Defense session to move to our session, if the organizer (Emily Albrecht) would agree to this.

Any other thoughts?

Tony

From: "Karst,Stephanie" <skarst@ufl.edu>
Date: Wednesday, June 10, 2020 at 8:37 AM
To: "Fehr, Anthony" <arfehr@ku.edu>, "rchanna1@uthsc.edu" <rchanna1@uthsc.edu>
Subject: coronavirus workshop


Anthony and Rudra, following up on the slack conversation about no female presenters in your workshop I would like to verify that you invited all the abstract presenters from the scheduled in-person meeting. I looked through those and there were definitely females scheduled to present so my conclusion is that all the females declined your offer to present in the virtual workshop. **Is this accurate?**

Although this is out of our control (we can't force people to present), it does concern me that our female trainees aren't taking advantage of this opportunity and it makes me want to dig deeper and see if this was a common occurrence in our workshops.

Best, Stephanie

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539



correlates of protection

Frieman, Matthew <MFrieman@som.umaryland.edu>

Mon 11/25/2019 12:50 PM

To:Rob Haupt <rob_haupt@umaryland.edu>

2 attachments (412 KB)

1-s2.0-S0264410X19314264-main.pdf; ATT00001.htm;

Connecting to Marisa

Frieman, Matthew <MFrieman@som.umaryland.edu>

Thu 10/29/2020 2:45 PM

To:McGrath, Marisa <Marisa.McGrath@som.umaryland.edu>;dmilton@umd.edu <dmilton@umd.edu>;Filbert Hui-peh Hong <fhong@umd.edu>

Here is Marisas email. Please add her to Box and Simuldoc and Slack!

Thanks

Matt

Matthew Frieman
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St, Room 380
Baltimore, MD 21201

Fwd: Invite your teammates to Slack

Frieman, Matthew <MFrieman@som.umaryland.edu>

Sat 2/15/2020 5:35 PM

To:Sheahan, Timothy Patrick <sheahan@email.unc.edu>;Menachery, Vineet <vimenach@UTMB.EDU>;Lisa E. E. Gralinski <lgralins@email.unc.edu>

Hi all

As inaugural members of the SARS2 Slack channel, I knight you as OG members. (Lapel pins to follow, sorry Lisa).

You can send the link below to whoever you think you want on here and that will be useful, but not annoying.

I get to be the only annoying one on here.

My house, my rules!

Matt

Begin forwarded message:

From: "Slack" <feedback@slack.com>
Subject: Invite your teammates to Slack
Date: February 15, 2020 at 5:04:34 PM EST
To: mfrieman@som.umaryland.edu
Reply-To: feedback@slack.com

👋 Matt Frieman, forward this email to the people you'd like to invite to your workspace. Anyone who has this message can use the link below to sign up. [Manage your invite link](#)



Join SARS2 on Slack


Matt Frieman has created the new Slack workspace **SARS2**. You can use the link below to join this workspace — it only takes a minute to create an account!

Use this link to get started:

https://join.slack.com/t/sars2/shared_invite/enQtOTQyODA2MzUwMjc1LTEzMmEwOWMxMTgwZTZhZWYyMDUwZmRIZjQ0ODNkNzY1ZDbmYTdlYjk5N2I3NGM1ZjBmZjkxYjQzNGViMDliZjA

What is Slack?

Slack makes it easy for teams to communicate and get work done together. [See Slack in action.](#)



Made by Slack Technologies, Inc
500 Howard Street San Francisco, CA 94105 United States

[Our Blog](#) • [Email Preferences](#) • [Policies](#)

Matthew Frieman, PhD
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

today stuff

Frieman, Matthew <MFrieman@som.umaryland.edu>

Sun 3/22/2020 12:32 PM

To:Krystal Matthews <krystallmatthews@gmail.com>;Weston, Stuart <SWeston@som.umaryland.edu>;Rob Haupt <rob_haupt@umaryland.edu>;Logue, James <James.Logue@som.umaryland.edu>;Hammond, Holly <HHammond@som.umaryland.edu>

I just put stuff for today on Slack. Can everyone check and respond?

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

Re: invoice for culturing of samples RSTARS Number R31-1883000

Frieman, Matthew <MFrieman@som.umd.edu>

Tue 12/22/2020 1:31 PM

To:dmilton@umd.edu <dmilton@umd.edu>;Maurice Rocque <mrocque@umd.edu>

Cc:Filbert H. Hong <fhong@umd.edu>

We are going to correct on our side and send another invoice. We didn't know what the budget was for these so just billed for 120 samples. Will reduce to 100 and send back.

Matt

Matthew Frieman
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St, Room 380
Baltimore, MD 21201

From: Donald K. Milton <dmilton@umd.edu>

Date: Tuesday, December 22, 2020 at 12:40 PM

To: Maurice Rocque <mrocque@umd.edu>

Cc: Filbert H. Hong <fhong@umd.edu>, Frieman, Matthew <MFrieman@som.umd.edu>

Subject: Re: invoice for culturing of samples RSTARS Number R31-1883000

I'm not sure why they didn't invoice for the \$20K budgeted. I've copied him and also sent a Slack message. He has a much larger CDC budget (but that contract is short -- so we need to make sure he's invoicing on that) for a lot more. Is there a way you can split this and pay the extra from the CDC budget allocation?

Donald K Milton, MD, DrPH
Professor, Environmental & Occupational Health
School of Public Health | University of Maryland
<https://stopcovid.umd.edu>, <http://blog.umd.edu/catch/>

On Tue, Dec 22, 2020 at 12:10 PM Maurice Rocque <mrocque@umd.edu> wrote:

Hi Don and Filbert,

We have \$20,000 budgeted for Matt Frieman for the Gates project. However, he wants to invoice for \$24,000. Is this okay? This would be a 12% budget change so technically we'll have to request permission from the sponsor.

Thanks,

Maurice Rocque

Assistant Director, Finance and Administration

Maryland Institute for Applied Environmental Health

School of Public Health

University of Maryland, College Park

----- Forwarded message -----

From: **Abeduo, Ogechi <OAbeduo@som.umd.edu>**

Date: Mon, Dec 21, 2020 at 4:24 PM

Subject: RE: invoice for culturing of samples RSTARS Number R31-1883000

To: Maurice Rocque <mrocque@umd.edu>
Cc: Frieman, Matthew <MFrieman@som.umaryland.edu>, Dillen, Carly <CDillen@som.umaryland.edu>, Adewunmi, Olugbenga <OAdewunmi@som.umaryland.edu>

Hello Maurice,

Please see attached. Kindly let me know if anything else is needed.

Thank you,

Ogechi Abeduo, MBA.

Contracts & Grants Accountant
Dept of Microbiology & Immunology
University of Maryland School of Medicine
685 W. Baltimore Street
HSF 1 380
Baltimore, MD 21201
Phone: 410-706-3341
Fax: 410-706-6970



From: Maurice Rocque <mrocque@umd.edu>
Sent: Monday, December 14, 2020 9:47 AM
To: Abeduo, Ogechi <OAbeduo@som.umaryland.edu>
Cc: Frieman, Matthew <MFrieman@som.umaryland.edu>; Dillen, Carly <CDillen@som.umaryland.edu>
Subject: Re: invoice for culturing of samples

Hello Ogechi,

I just wanted to follow up on this.

Thanks,

Maurice Rocque

Assistant Director, Finance and Administration
Maryland Institute for Applied Environmental Health
School of Public Health
University of Maryland, College Park

On Mon, Dec 7, 2020 at 4:18 PM Abeduo, Ogechi <OAbeduo@som.umaryland.edu> wrote:

Hello Maurice,

I will work on this and get back to you as soon as possible.

Thank you,

Ogechi Abeduo, MBA.

Contracts & Grants Accountant
Dept of Microbiology & Immunology
University of Maryland School of Medicine

685 W. Baltimore Street
HSF 1 380
Baltimore, MD 21201
Phone: 410-706-3341
Fax: 410-706-6970



From: Maurice Rocque <mrocque@umd.edu>
Sent: Monday, December 7, 2020 3:02 PM
To: Frieman, Matthew <MFrieman@som.umaryland.edu>
Cc: Abeduo, Ogechi <OAbeduo@som.umaryland.edu>; Dillen, Carly <CDillen@som.umaryland.edu>
Subject: Re: invoice for culturing of samples

Hello Ogechi and Carly,

I just need an invoice billing the University of Maryland, College Park for culturing cells for Dr. Donald Milton's COVID-19 project. Matt quoted us \$200 per sample. He can let you know how many samples to bill us for. The invoice should also include the RSTARS information.

Let me know if you have any questions.

Best Regards,

Maurice Rocque

Assistant Director, Finance and Administration
Maryland Institute for Applied Environmental Health
School of Public Health
University of Maryland, College Park

On Mon, Dec 7, 2020 at 2:57 PM Frieman, Matthew <MFrieman@som.umaryland.edu> wrote:

This is not billing for either of those. This is a separate grant that we are not officially listed on through the Gates Foundation with Don Milton as PI. We are just a contractor on it. So they want an invoice to be able to process and send funds back to us.

Maurice Rocque is the budget admin for Milton. Maurice can you tell us how you want us to bill this?

Matt

Matthew Frieman
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St, Room 380
Baltimore, MD 21201

From: Abeduo, Ogechi <OAbeduo@som.umaryland.edu>
Date: Monday, December 7, 2020 at 2:17 PM
To: Frieman, Matthew <MFrieman@som.umaryland.edu>
Subject: FW: invoice for culturing of samples

Dr. Frieman,

Per my record, you currently have two collaborations with college park:

1. University of MD at College Park : Contagious Phenotypes of Acute 08/14/18-7/31/2020
2. MPower COVID-19 Respond Fund (with Drs. Thomas Fuerst, Gilad Ofek, Brian Pierce, Alexander Andrianov, and Matthew Frieman) 8/15/2020-6/15/2021

Is this billing for any of the above or is it for an entirely different project? I want to be sure we are billing on the right project.

Ogechi Abeduo, MBA.

Contracts & Grants Accountant

Dept of Microbiology & Immunology

University of Maryland School of Medicine

685 W. Baltimore Street

HSF 1 380

Baltimore, MD 21201

Phone: 410-706-3341

Fax: 410-706-6970



From: Maurice Rocque <mrocque@umd.edu>

Sent: Thursday, December 3, 2020 4:42 PM

To: Frieman, Matthew <MFrieman@som.umaryland.edu>

Cc: Abeduo, Ogechi <OAbeduo@som.umaryland.edu>

Subject: Re: invoice for culturing of samples

Thank you Matt.

Ogechi: I just need an invoice billing the University of Maryland, College Park for culturing cells for Dr. Donald Milton's COVID-19 project. Matt quoted us \$200 per sample. He can let you know how many samples to bill us for. The invoice should also include the RSTARS information.

Please let me know if you need more information.

Best Regards,

Maurice Rocque

Assistant Director, Finance and Administration

Maryland Institute for Applied Environmental Health

School of Public Health

University of Maryland, College Park

On Thu, Dec 3, 2020 at 12:38 PM Frieman, Matthew <MFrieman@som.umaryland.edu> wrote:

Maurice

I want to connect you with Ogechi Abeduo, my account manager to figure out how to invoice for this.

Matt

Matthew Frieman
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St, Room 380
Baltimore, MD 21201

From: Maurice Rocque <mrocque@umd.edu>
Date: Thursday, December 3, 2020 at 10:02 AM
To: Frieman, Matthew <MFrieman@som.umaryland.edu>
Subject: invoice for culturing of samples

Hi Matt,

I hope you're doing well.

When you get a chance, can you please have your finance office send me an invoice for the costs your lab has incurred for culturing samples for Don's Gates Foundation project? Please ask them to include the RSTARS information on the invoice

We're not using a subcontract so the payment process should be much smoother. Let me know if you have any questions.

Best Regards,

Maurice Rocque
Assistant Director, Finance and Administration
Maryland Institute for Applied Environmental Health
School of Public Health
University of Maryland, College Park

Re: Budget for COVID work with hydrogels for impactor

Frieman, Matthew <MFrieman@som.umd.edu>

Mon 8/3/2020 9:44 AM

To:dmilton@umd.edu <dmilton@umd.edu>

Cc:P. Jacob Bueno de Mesquita <jbueno@umd.edu>

Sure, that's fine. That will make it easy.

On Aug 3, 2020, at 9:43 AM, Donald K. Milton <dmilton@umd.edu> wrote:

I'm trying to add this to the BMGF application that we are submitting (maybe today). So, to make this work, I'm probably going to just budget for a cost per sample (for now). Is \$200/ea sufficient?

On Thu, Jul 30, 2020 at 6:30 PM Donald K. Milton <dmilton@umd.edu> wrote:

Excellent.

If this works for preserving culturability, I'm thinking that we should look at using this as a replacement for the condensate collection. I would consider building a 0.5 or 0.3 μm impactor. This would have a much more forceful jet impinging on the plate. We could start by testing with the current 1 μm impactor in the G-II, but running it dry. That would give a first look. If we can feel comfortable with giving up the particles < 0.5 or 0.3 μm we can then have a much simpler, more portable instrument. The sample handling would be far easier, and we could have lots of spare parts and turn around and sample much faster.

Don

On Thu, Jul 30, 2020 at 5:46 PM Frieman, Matthew <MFrieman@som.umd.edu> wrote:

Costs are a little bit higher on our end. I don't know how much you are thinking. I guess \$50K for us for 4 or 5 rounds of testing with qPCR, titer and IFA on cells?

Matt

On Jul 30, 2020, at 2:51 PM, Donald K. Milton <dmilton@umd.edu<mailto:dmilton@umd.edu>>> wrote:

I'm thinking that if this looks good based on the culture testing, that we should look at making a new sampler that is a cascade inertial impactor with a 5 μm and a 0.5 μm impactor each with a mucin hydrogel collection surface. We can either then throw away the smaller particles, or we can put a downstream filter. An 80mm Sartorius gelatin filter can run at 116 lpm, might it be possible to make a mucin hydrogel filter at similar flows (~130 lpm)? This would move us away completely from the current growth and liquid capture regime and be much easier to operate.

Don

On Thu, Jul 30, 2020 at 11:53 AM Gregg Duncan <gaduncan@umd.edu<mailto:gaduncan@umd.edu>>> wrote:

Costs would not be significant on our end. Based on the numbers below including 3-4 rounds of testing, should be around \$5K to make our mucin hydrogels for the impactor. If there was room in the budget for a member of our lab (as an example, 20-25% effort for a grad student) to regularly prepare the gels, that would be helpful.

On a technical note, we have two types of gels we can make with the same physical properties but different mucin types (intestinal vs salivary). We are using the intestinal mucin gels for our studies now, but I would be interested in testing both in parallel.

Thanks,
Gregg

Gregg Duncan, PhD
Assistant Professor
Fischell Department of Bioengineering
University of Maryland
301-405-7397
gaduncan@umd.edu<mailto:gaduncan@umd.edu>
<http://duncan.umd.edu><http://duncan.umd.edu/>

On Jul 29, 2020, at 11:45 PM, Donald K. Milton <dmilton@umd.edu<mailto:dmilton@umd.edu>>> wrote:

This is going to be nested in a much larger ask for the whole year's nCoV work. I don't know how much we can get. But, we could also just write it up as a small R21.

On Wed, Jul 29, 2020 at 11:21 PM Frieman, Matthew <MFrieman@som.umd.edu<mailto:MFrieman@som.umd.edu>>> wrote:
So we should budget for say 3 or 4 rounds of this kind of testing?

Don, is there a budget range to shoot for?

On Jul 29, 2020, at 11:12 PM, Donald K. Milton <dmilton@umd.edu<mailto:dmilton@umd.edu>>><mailto:dmilton@umd.edu<mailto:dmilton@umd.edu>>>> wrote:

Great -- can y'all get together a ROM budget by COB tomorrow?

On Wed, Jul 29, 2020 at 6:26 PM P. Jacob Bueno de Mesquita <jbueno@umd.edu<mailto:jbueno@umd.edu>>><mailto:jbueno@umd.edu<mailto:jbueno@umd.edu>>>> wrote:

Hi Matt,

That sounds great, thank you.

If we have trouble recovering culturable virus and want to try altering the hydrogel, that could lead to an additional round of 21 samples per hydrogel alteration?

This is hinging on the idea that the vero culture system will work. It sounds like we will get some sense for that in the coming days having delivered you a bunch of samples today.

Perhaps you have a strategy for thinking about building in additional materials in a budget to support additional process of experimentation assuming a likelihood for iteration?

Thanks,

Jake

On Wed, Jul 29, 2020 at 6:16 PM Frieman, Matthew

<MFrieman@som.umaryland.edu<mailto:MFrieman@som.umaryland.edu>>> wrote:

<MFrieman@som.umaryland.edu<mailto:MFrieman@som.umaryland.edu>>>>> I think triplicate samples for each doped in concentration and probably 5 concentrations with 2 sets of negative controls? So maybe 21 samples total?

Read outs would be at 48 hour post infection of Vero cells with RNA positive samples plus testing titer? Sound ok?

Matt

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539<<tel:410-706-2539>>

On Jul 29, 2020, at 6:14 PM, P. Jacob Bueno de Mesquita <jbueno@umd.edu<mailto:jbueno@umd.edu>>> wrote:

Hi Matt,

How many positive culture samples (perhaps at with different levels of seeding quantity) would lead you to have confidence that we are able to successfully capture and culture virus with the new hydrogel impactor?

Thanks,

Jake

On Wed, Jul 29, 2020 at 3:14 PM Frieman, Matthew

<MFrieman@som.umaryland.edu<mailto:MFrieman@som.umaryland.edu>>> wrote:

<MFrieman@som.umaryland.edu<mailto:MFrieman@som.umaryland.edu>>>>> How many samples are we talking about for testing?

Matt

On Jul 29, 2020, at 2:40 PM, Donald K. Milton <dmilton@umd.edu<mailto:dmilton@umd.edu>>> wrote:

I may have a source for funding this work -- can you all work with Jake and come up with a budget for design, production, and testing of these new sampling hydrogels?

--

Donald K Milton, MD, DrPH
Professor, Environmental & Occupational Health
School of Public Health | University of Maryland
<https://go.umd.edu/stopcovid>, <http://blog.umd.edu/catch/>

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology

University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

--
P. Jacob Bueno de Mesquita, PhD
Postdoctoral Researcher
Maryland Institute for Applied Environmental Health
School of Public Health | University of Maryland, College Park
jbueno@umd.edu<mailto:jbueno@umd.edu><mailto:jbueno@umd.edu>> | 401.932.1950
<https://go.umd.edu/stopcovid><<https://slack-redir.net/link?url=https%3A%2F%2Fgo.umd.edu%2Fstopcovid>>

--
P. Jacob Bueno de Mesquita, PhD
Postdoctoral Researcher
Maryland Institute for Applied Environmental Health
School of Public Health | University of Maryland, College Park
jbueno@umd.edu<mailto:jbueno@umd.edu><mailto:jbueno@umd.edu><mailto:jbueno@umd.edu>> | 401.932.1950
<https://go.umd.edu/stopcovid><<https://slack-redir.net/link?url=https%3A%2F%2Fgo.umd.edu%2Fstopcovid>>

--
Donald K Milton, MD, DrPH
Professor, Environmental & Occupational Health
School of Public Health | University of Maryland
<https://go.umd.edu/stopcovid>, <http://blog.umd.edu/catch/>

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

--
Donald K Milton, MD, DrPH
Professor, Environmental & Occupational Health
School of Public Health | University of Maryland
<https://go.umd.edu/stopcovid>, <http://blog.umd.edu/catch/>

--
Donald K Milton, MD, DrPH
Professor, Environmental & Occupational Health
School of Public Health | University of Maryland
<https://go.umd.edu/stopcovid>, <http://blog.umd.edu/catch/>

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

Donald K Milton, MD, DrPH
Professor, Environmental & Occupational Health
School of Public Health | University of Maryland
<https://stopcovid.umd.edu>, <http://blog.umd.edu/catch/>

--

Donald K Milton, MD, DrPH
Professor, Environmental & Occupational Health
School of Public Health | University of Maryland
<https://stopcovid.umd.edu>, <http://blog.umd.edu/catch/>

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539
[REDACTED]

Frieman IACUC Protocol Renewal

Frieman, Matthew <MFrieman@som.umaryland.edu>

Fri 11/6/2020 4:01 PM

To:IACUC Department Mailbox <iacuc@som.umaryland.edu>;McCulle, Stacey <smcculle@som.umaryland.edu>
Cc:Dillen, Carly <CDillen@som.umaryland.edu>

16 attachments (10 MB)

University of Maryland Baltimore (TMRSS2) Task Order #7 Project Work to Amended & Restated RCA 2.12.20 - signed.pdf; University of Maryland Baltimore (MERS and Other Coronavirus Infection) Amendment #2 to Amended and Restated RCA 2.12.20 - signed.pdf; UMD - 75A50120C00023 (signed).pdf; Template_IBC_Mod_Approval (3).pdf; Template_IBC_Mod_Approval (3)-2.pdf; HSF1 AUP-Addendum_PI-Managed-Satellite-Facility 11042020 CD.docx; HCoV BSL2 AUP-Addendum_Hazardous-Agent_Pathogenic-Organisms_09.2020[56566].docx; BRB AUP-Addendum_PI-Managed-Satellite-Facility_10292020 CD.docx; AUP-Addendum_Hazardous-Agent_Chemical-Level-1_11062020.docx; AUP-Addendum_All-Species-(x-NHP)-Enrichment-Socialization_10292020 CD.docx; AUP Personnel Amendment 11062020 HHammond JLogue; Animal-Use-Protocol-Form_11062020 CD.docx; 11062020 AUP-Addendum_Rodent-Breeding.docx; 4369067_Egrant.pdf; 4360150_Egrant.pdf; 321Z48D_04BYXJ5G4000GZP.pdf;

Hi Stacey

Here is our IACUC renewal forms. I believe all is attached. If we are missing anything or there are any questios, please let us know.

Thanks

Matt

Matthew Frieman
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St, Room 380
Baltimore, MD 21201

Re: Speaker/panelist invitation: Union of European Neonatal & Perinatal Societies (UENPS) web based seminar

Frieman, Matthew <MFrieman@som.umaryland.edu>

Thu 9/17/2020 9:56 AM

To:Condit, Richard C. <condit@UFL.EDU>

Rich

I know all 3 of them well and talk to all of them on a group Slack channel almost every day. Any of them would be great and a good choice. If you want Lisa as a female scientist on here, that's perfect with me. I am sure I can coordinate with her on our talks so we split up the topics. All 4 of us are working on all of these aspects so it would be fine to do this together with them.

If you want to send an invite to her, you don't have to pass it by me.

Thanks!

Matt

Matthew Frieman
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St, Room 380
Baltimore, MD 21201

From: "Condit, Richard C." <condit@UFL.EDU>

Date: Thursday, September 17, 2020 at 9:51 AM

To: Matthew Frieman <MFrieman@som.umaryland.edu>

Subject: RE: Speaker/panelist invitation: Union of European Neonatal & Perinatal Societies (UENPS) web based seminar

Matt,

I have looked at Vineet and Tim. I know neither of them but they look great. I have also been considering Lisa Gralinsky, who I also don't know but have knowledge of via Kathy Spindler; Lisa seems to track with the same pool of young coronavirologists. I suppose my only real reservation about any of these choices is that all are pretty junior, but that's not necessarily actually a problem, especially in this venue. Lisa would add gender balance, though since we have Carolyn that is not essential.

The most important things are that they are good communicators – we will be addressing a clinical audience in an education rather than research context – and that you would be comfortable coordinating with them to put together back to back presentations that cover the topic comprehensively and are not redundant. By topic I mean the fundamental virology, pathogenesis, immunology, therapy and prevention.

I feel like I'm asking a lot of you with this, but I trust your judgement and given my lack of knowledge of these people and their expertise I'm hoping you would be willing to guide the decision as to who would be best to approach first given all of these considerations, and that you would feel comfortable working with them to perfect the presentations. I can draft an invitation from both of us that makes all this clear and run it by you before sending it, unless you think a different approach would be better.

Thanks again for your help. Let me know what you think.

R

From: Frieman, Matthew <MFrieman@som.umd.edu>

Sent: Wednesday, September 16, 2020 4:21 PM

To: Condit, Richard C. <condit@UFL.EDU>

Subject: Re: Speaker/panelist invitation: Union of European Neonatal & Perinatal Societies (UENPS) web based seminar

[External Email]

Hi Rich

I would be happy to help and present. Let me know what else you need from me for this. I can help with other speakers too if you want. I think Vineet Menachery or Tim Sheahan would be great.

Matt

Matthew Frieman
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St, Room 380
Baltimore, MD 21201

From: "Condit, Richard C." <condit@UFL.EDU>

Date: Wednesday, September 16, 2020 at 5:09 PM

To: Matthew Frieman <MFrieman@som.umd.edu>

Subject: Speaker/panelist invitation: Union of European Neonatal & Perinatal Societies (UENPS) web based seminar

Matt,

I am helping a University of Florida pediatrician friend of mine, Joseph Neu, with a web-based seminar on COVID-19 organized by Union of European Neonatal & Perinatal Societies (UENPS) in collaboration with the International Postgraduate Organization for Knowledge Transfer Research and Teaching Excellent Students (IPOKRATES). Joseph is the current Chairman of the IPOKRATES foundation. The seminar is an international educational forum focused on an overview of the most critical aspects of how the current COVID 19 pandemic affects pregnant women, the fetus, the newborn, young children and families. I have attached a very brief outline of the seminar. I invite you to participate along with two other speaker/panelists, plus ourselves (as moderators) in Session 1 of the seminar, which is scheduled for Thursday October 15, from 5:00 PM to 7:45 PM CEST (11:00 AM – 1:45 PM Eastern Daylight Time). Details follow.

The session would focus on the essential virology, pathogenesis and immunology of SARS-CoV-2 and COVID-19, and the potential for infection of the fetus. The session would consist of a 30 minute presentation by each of three speaker/panelists followed by a 45 minute panel discussion including the three speaker/panelists plus the moderators addressing questions submitted from the audience and managed by the UENPS-IPOKRATES staff. (An additional 30 minutes total is provided for introduction of the session and summarization of the talks, provided by the moderators.) Carolyn Coyne has agreed to present the basic science of the placental barrier to transmission with insights in relation to SARS-CoV-2. We envision you and another yet-to-be-identified coronavirologist collaborating to cover the basics of the virus and the disease. The focus should be on education over original research with an understanding that the audience will be primarily if not exclusively clinicians. We want the session to be maximally comprehensive and minimally redundant among the speakers. I have not yet identified a second coronavirologist but I have a list of candidates and you probably would have more ideas. If you are willing to participate, I would prefer to vet the second speaker with you to make it the best it can be.

From my perspective, this is a great opportunity to share knowledge and understanding in an international venue to help find a path through the pandemic. I hope that you might find this an interesting enterprise and that you will be able to assist us in this effort.

Thanks very much for your consideration.

Sincerely,

Rich

Richard C. Condit, Ph.D.
Emeritus Professor
University of Florida
Gainesville, Florida

Re: checking in

Frieman, Matthew <MFrieman@som.umd.edu>

Wed 9/30/2020 4:44 PM

To: Margaret Adele Scull <scull@umd.edu>

Cc: Rosenberg, Brad <brad.rosenberg@mssm.edu>

Hi Sorry!

We havnt done this cloning. If Brad's lab can pick up the slack, I am all for it.

I would love a call soon to talk about CoVs and what we can do together. Can we find a time next week to chat? How about Wednesday or Thursday at 3?

Matt

From: Margaret Adele Scull <scull@umd.edu>

Date: Wednesday, September 30, 2020 at 4:15 PM

To: Matthew Frieman <matt.frieman@gmail.com>, Matthew Frieman <MFrieman@som.umd.edu>

Cc: "Rosenberg, Brad" <brad.rosenberg@mssm.edu>

Subject: Fwd: checking in

Hi Matt,

Just resending my email below to put it back on the top of your pile :)

Hope all is well!!

Meg

Begin forwarded message:

From: Margaret Adele Scull <scull@umd.edu>

Subject: checking in

Date: September 20, 2020 at 10:11:39 PM EDT

To: Matt Frieman <matt.frieman@gmail.com>, "Frieman, Matthew" <mfrieman@som.umd.edu>

Cc: "Rosenberg, Brad" <brad.rosenberg@mssm.edu>

Hi Matt!

Hope all is well!

Brad and I were catching up on various projects earlier today and wanted to touch base again on setting up the coronavirus PCR for the BLS2 viruses.

As we both recognize how incredibly swamped you are, we didn't know if you had already started the cloning, or if it would make more sense for one of our students to take the lead on this with your input? I think Emma in Brad's lab would be happy to step up! Alternatively, do I remember correctly that Krzysztof Pyrc has made some of these standards? Would it be an idea to reach out to him to save everyone the time?

Let me know what you think makes the most sense (we can also discuss more via Zoom / phone if you like!) — we're pretty excited about this experiment :)

Best,
Meg

Margaret A. Scull, Ph.D.

Assistant Professor, Dept. of Cell Biology & Molecular Genetics
University of Maryland, College Park
3134 Bioscience Research Building
College Park, MD 20742
(301) 405-6846

Re: checking in

Frieman, Matthew <MFrieman@som.umaryland.edu>

Wed 10/7/2020 6:24 PM

To: Margaret Adele Scull <scull@umd.edu>

Cc: Rosenberg, Brad <brad.rosenberg@mssm.edu>

NL63 is supposed to be better in LMCK2 cells. Never had much luck growing it well. Works best in trans wells compare to anything else.

From: Margaret Adele Scull <scull@umd.edu>

Sent: Wednesday, October 7, 2020 4:50:19 PM

To: Frieman, Matthew <MFrieman@som.umaryland.edu>

Cc: Rosenberg, Brad <brad.rosenberg@mssm.edu>

Subject: Re: checking in

Got it - thanks!

What about NL63? Would Huh7's work there as well?

On Oct 7, 2020, at 4:48 PM, Frieman, Matthew <MFrieman@som.umaryland.edu> wrote:

Hey!

Nice to talk to you both today.

We grow in Huh7 for both OC43 and 229E. Huh7.5 didn't work that well for us.

Matt

From: Margaret Adele Scull <scull@umd.edu>

Date: Thursday, October 1, 2020 at 9:17 PM

To: "Rosenberg, Brad" <brad.rosenberg@mssm.edu>

Cc: Matthew Frieman <MFrieman@som.umaryland.edu>

Subject: Re: checking in

Ok!

I set up a zoom meeting for Wed 10/7 @ 3pm. See you both then!

Meg

Margaret Adele Scull is inviting you to a scheduled Zoom meeting.

Topic: CoV Project Discussion

Time: Oct 7, 2020 03:00 PM Eastern Time (US and Canada)

Join Zoom Meeting

<https://umd.zoom.us/j/5884103172>

Meeting ID: 588 410 3172

One tap mobile

+13017158592,,5884103172# US (Germantown)

+13126266799,,5884103172# US (Chicago)

Dial by your location

+1 301 715 8592 US (Germantown)

+1 312 626 6799 US (Chicago)

+1 929 436 2866 US (New York)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)
+1 669 900 6833 US (San Jose)

Meeting ID: 588 410 3172

Find your local number: <https://umd.zoom.us/u/aecrAxel7Y>

On Sep 30, 2020, at 6:26 PM, Rosenberg, Brad <brad.rosenberg@mssm.edu> wrote:

I can't do Thursday, but Wednesday 10/07 works well. 3pm works for me.

Very much looking forward!

Brad

--

Brad R. Rosenberg, M.D., Ph.D.
Assistant Professor
Department of Microbiology
Icahn School of Medicine at Mount Sinai

On Sep 30, 2020, at 4:46 PM, Margaret Adele Scull <scull@umd.edu> wrote:

USE CAUTION: External
Message.

Hello!

Yes! Let's chat — I can do next Wednesday afternoon (after 1pm) or Thursday at 3 (but have another call at 4pm, just FYI).

Brad?

On Sep 30, 2020, at 4:44 PM, Frieman, Matthew
<MFrieman@som.umaryland.edu> wrote:

Hi Sorry!

We havnt done this cloning. If Brad's lab can pick up the slack, I am all for it.

I would love a call soon to talk about CoVs and what we can do together. Can we find a time next week to chat? How about Wednesday or Thursday at 3?

Matt

From: Margaret Adele Scull <scull@umd.edu>
Date: Wednesday, September 30, 2020 at 4:15 PM

To: Matthew Frieman <matt.frieman@gmail.com>, Matthew Frieman <MFrieman@som.umd.edu>
Cc: "Rosenberg, Brad" <brad.rosenberg@mssm.edu>
Subject: Fwd: checking in

Hi Matt,
Just resending my email below to put it back on the top of your pile :)
Hope all is well!!
Meg

Begin forwarded message:

From: Margaret Adele Scull <scull@umd.edu>
Subject: checking in
Date: September 20, 2020 at 10:11:39 PM EDT
To: Matt Frieman <matt.frieman@gmail.com>,
"Frieman, Matthew"
<mfrieman@som.umd.edu>
Cc: "Rosenberg, Brad" <brad.rosenberg@mssm.edu>

Hi Matt!

Hope all is well!

Brad and I were catching up on various projects earlier today and wanted to touch base again on setting up the coronavirus PCR for the BLS2 viruses.

As we both recognize how incredibly swamped you are, we didn't know if you had already started the cloning, or if it would make more sense for one of our students to take the lead on this with your input? I think Emma in Brad's lab would be happy to step up! Alternatively, do I remember correctly that Krzysztof Pyrc has made some of these standards? Would it be an idea to reach out to him to save everyone the time?

Let me know what you think makes the most sense (we can also discuss more via Zoom / phone if you like!) — we're pretty excited about this experiment :)

Best,
Meg

Margaret A. Scull, Ph.D.

Assistant Professor, Dept. of Cell Biology & Molecular Genetics
University of Maryland, College Park
3134 Bioscience Research Building
College Park, MD 20742
(301) 405-6846

Margaret A. Scull, Ph.D.

Assistant Professor, Dept. of Cell Biology & Molecular Genetics

University of Maryland, College Park
3134 Bioscience Research Building
College Park, MD 20742
(301) 405-6846

Margaret A. Scull, Ph.D.

Assistant Professor, Dept. of Cell Biology & Molecular Genetics
University of Maryland, College Park
3134 Bioscience Research Building
College Park, MD 20742
(301) 405-6846

Re: NoA: 1 R01 AI148166-01A1 PI: Frieman, Matthew Action Form #67010

Frieman, Matthew <MFrieman@som.umd.edu>

Thu 6/18/2020 2:40 PM

To: Goodlett, David <goodlett@umaryland.edu>

Cc: Ryan Langlois <langlois@umn.edu>; jhasday@umaryland.edu <jhasday@umaryland.edu>

2 attachments (4 MB)

Final Specific Aims.Diabetes.R01.102019.docx; 4369067_Egrant.pdf;

Ha! You and me both!

Here is what we submitted.

On Jun 18, 2020, at 1:02 PM, Goodlett, David <goodlett@umaryland.edu> wrote:

OK, Matt

Don't even recall what we planned!

Dave

David R Goodlett, PhD
Visiting Professor, Microbial Pathogenesis
Dental School, University of Maryland
650 West Baltimore Street, Baltimore, MD 21201
Contact: 410.706.2263 & goodlett@umaryland.edu

Organizing Committee, MSBM.ORG
msbm.dubrovnik@gmail.com

Editor, Rapid Communications in Mass Spectrometry
rcm_sea@msn.com

goodlettlab.org & twitter.com/goodlettlab1

From: Frieman, Matthew <MFrieman@som.umd.edu>

Sent: Thursday, June 18, 2020 12:15 PM

To: Goodlett, David <goodlett@umaryland.edu>

Cc: Ryan Langlois <langlois@umn.edu>; jhasday <jhasday@umaryland.edu>

Subject: Re: NoA: 1 R01 AI148166-01A1 PI: Frieman, Matthew Action Form #67010

Thanks! I actually want to do what we planned in this grant too!

Breeding mice for the MERS project now but also want to try with SARS2 if everyone is game. Let me get some ideas together and will send over so we can discuss soon.

Matt

On Jun 18, 2020, at 11:50 AM, Goodlett, David <goodlett@umaryland.edu> wrote:

Indeed! Congrats

Cheers, Dave

David R Goodlett, PhD
Visiting Professor, Microbial Pathogenesis
Dental School, University of Maryland
650 West Baltimore Street, Baltimore, MD 21201
Contact: 410.706.2263 & goodlett@umaryland.edu

Organizing Committee, MSBM.ORG
msbm.dubrovnik@gmail.com

Editor, Rapid Communications in Mass Spectrometry
rcm_sea@msn.com

goodlettlab.org & twitter.com/goodlettlab1

From: Frieman, Matthew <MFrieman@som.umaryland.edu>
Sent: Thursday, June 18, 2020 10:58 AM
To: Goodlett, David <goodlett@umaryland.edu>; Ryan Langlois <langlois@umn.edu>; jhasday <jhasday@umaryland.edu>
Subject: Fwd: NoA: 1 R01 AI148166-01A1 PI: Frieman, Matthew Action Form #67010

Hey guys, good news!!

We got the MERS diabetes RO1 funded!

You should hear from our office here about budgets etc.

We are clearly doing this for MERS and SARS2 but we are excited to kick this off. I will email again soon for the upcoming plans. Excited to have this around for 5 years and hopefully more. Want to spin this for a SARS2 specific grant and getting out another paper from Kirsten on this too soon, when I have time to finish writing it.

Congratulations, will be in touch soon.

Matt

Begin forwarded message:

From: "Woods, Sarah" <SDiTizio@som.umaryland.edu>
Subject: Fwd: NoA: 1 R01 AI148166-01A1 PI: Frieman, Matthew Action Form #67010
Date: June 17, 2020 at 9:20:33 AM EDT
To: "Frieman, Matthew" <MFrieman@som.umaryland.edu>
Cc: "Abeduo, Ogechi" <OAbeduo@som.umaryland.edu>, "Adewunmi, Olugbenga" <OAdeunmi@som.umaryland.edu>

Your R01 just came in!

Thanks,
Sarah

Begin forwarded message:

From: "Starace, Michael" <mstarace@umaryland.edu>
Date: June 17, 2020 at 9:06:48 AM EDT
To: "Woods, Sarah" <SDiTizio@som.umaryland.edu>
Subject: Fwd: NoA: 1 R01 AI148166-01A1 PI: Frieman, Matthew Action Form #67010

Dear Sarah,

Please see the attached NOA and please make sure to review the special terms and conditions listed in it.

Thanks,

Michael Starace

Sponsored Programs Administrator

University of Maryland, Baltimore
Office of Research and Development
620 W. Lexington Street, 4th Floor
Baltimore, MD 21201
ph. (410)706-4748
fax (410)706-6630
mstarace@umaryland.edu
researchmatters.umaryland.edu

SPA Office Hours: 7:30 a.m.-5:00 p.m.(Monday-Friday)

AWS Out of Office: Timesheet Week Monday

Starting Monday, March 16, 2020, Sponsored Programs Administration will be working remotely to comply with the UMB Campus guidelines regarding the COVID-19 pandemic. While we will do our best to continue normal operations and work schedules, please understand that due to the nature of the situation, responses and actions may be delayed. We appreciate your patience during this unprecedented time.

<image001.jpg>

DISCLAIMER: This email -- including any attachments -- is a private communication for the sole use of the intended recipient/s and may contain CONFIDENTIAL or PRIVILEGED information. If you have received this email in error, please notify the sender immediately and destroy all copies of the original --including any attachments-- do not disclose the contents to another person, use the contents for any purpose, or store or copy the contents in any medium.

Begin forwarded message:

From: "Sorensen, Gregory J." <gsore001@umaryland.edu>
Subject: Fwd: NoA: 1 R01 AI148166-01A1 PI: Frieman, Matthew
Action Form #67010
Date: June 17, 2020 at 7:52:12 AM EDT
To: "Starace, Michael" <mstarace@umaryland.edu>

Good Morning,
Please put this into the Action Form and pull out the terms and conditions. Send a copy to the Department with the terms and conditions as well. Thanks

Greg J. Sorensen

Assistant Director, Sponsored Programs Admin.
Office of Research and Development
University of Maryland, Baltimore
620 W. Lexington Street, 4th Floor
Baltimore, Maryland 21201
Tel: (410) 706-1186

Fax: (410) 706-6630

Email: gsore001@umaryland.edu

(AWS Every other Monday, work hours 7am to 4pm)

Starting Monday, March 16, 2020, Sponsored Programs Administration will be working remotely to comply with the UMB Campus guidelines regarding the COVID-19 pandemic. While we will do our best to continue normal operations and work schedules, please understand that due to the nature of the situation, responses and actions may be delayed. We appreciate your patience during this unprecedeted time.

Begin forwarded message:

From: era-notify@mail.nih.gov
Subject: NoA: 1 R01 AI148166-01A1 PI: Frieman, Matthew
Date: June 17, 2020 at 12:30:12 AM EDT
To: nga@ordmail.umaryland.edu
Reply-To: eraNotifications@mail.nih.gov

Grant Number: 1 R01 AI148166-01A1
Principal Investigator: Frieman, Matthew Bryan
Project Title: Role of Diabetes in MERS Coronavirus
Pathogenesis
Institution: UNIVERSITY OF MARYLAND, BALTIMORE,
OFFICE OF RESEARCH AND DEVELOPMENT
CFDA: 93.855
OC: 41021
PCC: M51C B
Award Issue Date: 06/16/2020
Grants Management Officer: Khurana, Vandhana
Program Official: Stemmy, Erik
Grants Specialist: Carlisle, Tina
*** This is an automated notification - Please do not reply to this
message. ***

Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539



Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539



Matthew Frieman, PhD
Associate Professor
Department of Microbiology and Immunology
University of Maryland School of Medicine
685 West Baltimore St
Room 380
Baltimore, MD 21201

office: 410-706-2539



From: MFrieman@som.umaryland.edu

Sent: Fri, 21 Feb 2020 18:57:52 -0500

To: Meagan Deming <MDeming@ihv.umaryland.edu>, Damon Deming <damon_deming@med.unc.edu>

CC:

Subject: SARS2 slack channel!

Hey Deming's! I started a SAR2 group on Slack. Vineet, Tim and Gralinski are in so far. Come on in for the fun!

https://join.slack.com/t/sars2/shared_invite/enQtOTQyODA2MzUwMjc1LTEzMmEwOWMxMTgwZTZhZWYyMDUwZmRIZjQ0ODNkNzY1ZDBmYTdIYjk5N2I3NGM1ZjE

FriemanUniversity of MarylandSchool of Medicine410-706-2539 (work)443-791-7600 (cell)